Real-world safety profile of sonidegib: a disproportionality analysis based on the FDA adverse event reporting system
{{output}}
Background: Sonidegib is a novel treatment for locally advanced basal cell carcinoma (LaBCC) with demonstrated efficacy and safety in clinical trials. However, its real-world safety profile remains insufficiently characterized. T... ...
